估计Epstein-Barr病毒相关胃癌的全球负担:系统综述与Meta分析
该系统综述纳入1990年1月至2021年8月的220项研究、超过68,000例常规胃腺癌病例,汇总EBV在胃癌肿瘤细胞中的合并患病率为7.5%(95%CI 6.9%-8.1%),男性、弥漫型及近端部位患病率更高,淋巴上皮瘤样癌和残胃癌/胃 stump 癌中分别为75.9%和26.3%;作者假设EBV与胃癌存在因果关系并应用于GLOBOCAN 2020发病率,推测EBV疫苗每年或可预防81,000例EBV相关胃癌。
要点
- 常规胃腺癌中EBV合并患病率为7.5%(95%CI 6.9%-8.1%)。
- 男性较女性PR 2.1(95%CI 1.9-2.4),弥漫型较肠型PR 1.3(95%CI 1.1-1.5),近端较远端PR 2.5(95%CI 2.0-3.1)。
- 淋巴上皮瘤样胃癌中EBV患病率75.9%(95%CI 62.8%-85.5%),残胃癌/胃 stump 癌中26.3%(95%CI 22.2%-32.0%)。
核心结论
- 假设EBV与胃癌存在因果关系,将本研究发现应用于GLOBOCAN 2020胃癌发病率,提示开发有效EBV疫苗等一级预防措施全球每年或可预防81,000例EBV相关胃癌。
研究设计与样本
- 系统综述与Meta分析(PROSPERO CRD42020164473),检索1990年1月至2021年8月文献。
- 纳入220项符合条件的研究,涵盖超过68,000例常规胃腺癌病例。
- 按国家与地理区域计算EBV在胃肿瘤中的合并患病率及95%CI,覆盖常规腺癌、淋巴上皮瘤样胃癌和残胃癌/胃 stump 癌3种亚型。
- 对常规腺癌按性别、Lauren分型、胃癌分期和胃解剖部位计算患病率比值(PR)。
主要发现
- 常规胃腺癌肿瘤细胞中EBV合并患病率为7.5%(95%CI 6.9%-8.1%)。
- 男性较女性EBV患病率更高,PR 2.1(95%CI 1.9-2.4)。
- 弥漫型较肠型EBV患病率更高,PR 1.3(95%CI 1.1-1.5)。
- 近端区域较远端区域EBV患病率更高,PR 2.5(95%CI 2.0-3.1)。
- EBV患病率按胃癌分期无差异;淋巴上皮瘤样胃癌中为75.9%(95%CI 62.8%-85.5%),残胃癌/胃 stump 癌中为26.3%(95%CI 22.2%-32.0%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Evidence suggests that a fraction of new gastric cancer cases may be etiologically associated with Epstein-Barr virus (EBV), a known carcinogenic agent. We aimed to systematically explore the proportion of EBV-positive gastric cancer. METHODS: We did a systematic review (PROSPERO CRD42020164473) from January 1990 to August 2021. For each country and geographical region with available data, pooled prevalence and corresponding 95% confidence intervals (CIs) of EBV in gastric tumors were calculated for 3 subtypes of gastric adenocarcinoma (conventional adenocarcinoma, lymphoepithelioma-like gastric carcinoma, and remnant/stump carcinoma). For conventional adenocarcinoma, prevalence ratios (PRs) were presented for sex, Lauren's classification, gastric cancer stage, and anatomical location of the stomach. RESULTS: In 220 eligible studies including over 68,000 cases of conventional gastric adenocarcinoma, EBV prevalence in tumor cells was 7.5% (95% CI, 6.9%-8.1%) and was higher in men compared with women (PR, 2.1; 95% CI, 1.9-2.4), in diffuse type compared with intestinal type (PR, 1.3; 95% CI, 1.1-1.5), and in the proximal region compared with the distal region (PR, 2.5; 95% CI, 2.0-3.1). There was no difference in EBV prevalence by gastric cancer stage. EBV prevalence was 75.9% (95% CI, 62.8%-85.5%) among lymphoepithelioma-like gastric carcinoma and 26.3% (95% CI, 22.2%-32.0%) among remnant or stump carcinoma. CONCLUSIONS: Assuming a causal association between EBV and gastric cancer, our findings, when applied to the GLOBOCAN 2020 gastric cancer incidence, suggest that primary prevention such as the development of an effective EBV vaccine might prevent 81,000 EBV-associated gastric cancer cases worldwide annually.
引用
- Hirabayashi M, Georges D, Clifford GM, et al. Estimating the Global Burden of Epstein-Barr Virus-Associated Gastric Cancer: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2022. PMID: 35963539. doi:10.1016/j.cgh.2022.07.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。